M. Funke-Chambour (Bern, Switzerland), P. Molyneaux (London, United Kingdom), H. Ito (Nagasaki, Japan), M. Šterclová (Praha, Czech Republic)
Nigella sativa fixed oil, attenuates bleomycin-induced pulmonary fibrosis in a rat model
A. Abidi (Tunis , Tunisia), S. Bahri (Tunis , Tunisia), S. Ben Khamsa (Tunis , Tunisia), A. Legrand (Mons , Belgium)
|   |
The activity of nintedanib in a mouse model of severe allergic lung remodeling
L. Wollin (Biberach, Germany), C. Tomsic (Biberach, Germany), K. Erb (Biberach, Germany)
| |
Role of MUC4 in idiopathic pulmonary fibrosis
B. Ballester (Valencia, Spain), J. Milara (Valencia, Spain), R. Guijarro (Valencia, Spain), E. Morcillo (Madrid, Spain), J. Cortijo (Valencia, Spain)
| |
Implication of FGFR4 and its ligands in Idiopathic Pulmonary Fibrosis
A. Justet (Paris , France), S. Demagny (Paris , France), T. Boghanim (Paris , France), M. Jaillet (Paris , France), E. Marchal-Duval (Paris , France), A. Cazes (Paris , France), P. Mordant (Paris , France), Y. Castier (Paris , France), A. Mailleux (Paris , France), B. Crestani (Paris , France)
| |
Probe-based confocal laser-endomicroscopy imaging of differential auto-fluorescence of alveolar macrophages in diffuse lung diseases
K. Imaizumi (Toyoake, Japan), T. Okamura (Toyoake, Japan), T. Minezawa (Toyoake, Japan), Y. Gotoh (Toyoake, Japan), T. Horiguchi (Toyoake, Japan), Y. Mieno (Toyoake, Japan), S. Uozu (Toyoake, Japan), M. Kondo (Toyoake, Japan)
| |
Assessment of collagen in human idiopathic pulmonary fibrosis using second harmonics on Genesis 200
S. Royce (Clayton, Australia), C. Erdem (Clayton, Australia), A. Tan (JTC LaunchPad, Singapore), J. Jaffar (Clayton, Australia), G. Westall (Clayton, Australia), J. Bourke (Clayton, Australia), C. Samuel (Clayton, Australia), R. Widdop (Clayton, Australia)
| |
Investigating effects of nintedanib on biomarkers of ECM turnover in patients with IPF: the INMARK study
T. Maher (London, United Kingdom), S. Stowasser (Ingelheim, Germany), Y. Nishioka (Tokushima, Japan), E. White (Ann Arbor, Michigan, United States of America), V. Cottin (Lyon, France), I. Noth (Chicago, Illinois, United States of America), M. Selman (Mexico City, Mexico), D. Wachtlin (Ingelheim, Germany), C. Diefenbach (Biberach an der Riss, Germany), R. Jenkins (Nottingham, United Kingdom)
| |
Changes in neutrophil-lymphocyte and platelet-lymphocyte ratios and clinical outcomes in idiopathic pulmonary fibrosis
S. Bhorade (Chicago, IL, United States of America), E. Morgenthien (South San Francisco, CA, United States of America), J. Castle (South San Francisco, CA, United States of America), S. Limb (South San Francisco, CA, United States of America), J. Mehta (Chicago, IL, United States of America)
| |
Salvianolate can attenuate bleomycin-induced pulmonary epithelial-mesenchymal transition
f. wang (Qingdao , China), H. Jiang (Shanghai, China)
| |
Mucus matters: Ferrets demonstrate sustained fibrosis and mucociliary decrement following bleomycin-induced pulmonary fibrosis
J. Peabody (Birmingham, United States of America), S. Phillips (Birmingham, United States of America), V. Lin (Birmingham, United States of America), S. Bodduluri (Birmingham, United States of America), J. Lever (Birmingham, United States of America), R. Shei (Birmingham, United States of America), C. Hennessy (Denver, United States of America), E. Dobrinskikh (Denver, United States of America), V. Thannickal (Birmingham, United States of America), J. Engelhardt (Iowa City, United States of America), G. Tearney (Boston, United States of America), D. Schwartz (Denver, United States of America), S. Rowe (Birmingham, United States of America)
| |
Calgranulin B/S100A9 and KL-6 in bronchoalveolar lavage of patients with IPF and NSIP.
D. Bennett (Siena, Italy), G. Cillis (Siena, Italy), L. Bergantini (Siena, Italy), M. Salvini (Siena, Italy), P. Cameli (Siena, Italy), A. Fossi (Siena, Italy), R. Refini (Siena, Italy), P. Rottoli (Siena, Italy)
| |
ER stress is involved in alveolar epithelial cell dysfunction in hypoxia
e. Delbrel (Bobigny, France), A. Soumare (Bobigny, France), D. Marchant (Bobigny, France), T. Gille (Bobigny, France), J. Bernaudin (Bobigny, France), C. Planès (Bobigny, France), E. Boncoeur (Bobigny, France)
| |
Sustainability of use of an electronic health journal (patientMpower) for pulmonary fibrosis in a US patient support group (PF Warriors) over 180 days.
C. Edwards (Dublin, Ireland), B. Vick (Plano, United States of America), E. Costello (Dublin, Ireland)
| |
Assessment of blood biomarkers in patients with IPF under antifibrotic therapy
P. Wolf (Heidelberg, Germany), M. Schneider (Heidelberg, Germany), T. Muley (Heidelberg, Germany), M. Meister (Heidelberg, Germany), F. Herth (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany), N. Kahn (Heidelberg, Germany)
| |
TNF-a and IL-10 control macrophage expression of CXCL13, a prognostic biomarker of idiopathic pulmonary fibrosis
N. Bellamri (Rennes, France), C. Rousseau (Rennes, France), C. Morzadec (Rennes, France), M. Le Garrec (Rennes, France), B. Arnouat (Rennes, France), A. Joannes (Rennes, France), B. De La Latour (Rennes, France), F. Llamas-Guttierez (Rennes, France), L. VERNHET (Rennes, France), S. Jouneau (Rennes, France)
| |
Development of assays to evaluate inflammasomes’ activity in the peripheral blood and in alveolar macrophages in fibrotic lung diseases
A. Trachalaki (Herakleion, Greece), E. Tsitoura (Herakleion, Greece), E. Vasarmidi (Herakleion, Greece), E. Bibaki (Herakleion, Greece), G. Papastratigakis (Herakleion, Greece), G. Margaritopoulos (London, United Kingdom), N. Tzanakis (Herakleion, Greece), K. Antoniou (Herakleion, Greece)
| |
Definition of trypsin-like enzymes activity as the marker of severity of idiopathic pulmonary fibrosis
O. Karasyova (Dnepr, Ukraine), V. Rodionova (Dnepr, Ukraine), K. Gashynova (Dnepr, Ukraine)
| |
IPF exacerbations: Role of Respiratory tract infections
S. Malik (Wigan, United Kingdom), N. Kewalramani (Wigan, United Kingdom), A. Ashish (Wigan, United Kingdom), K. Butler (Wigan, United Kingdom)
| |